AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29792226 — intervention group
Group type: COMPARATOR
Intervention: Regular occupational therapy
Number of subjects: 118
Study 27016875 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) integrity
Number of subjects: 15
Study 25818388 — intervention group
Group type: EXPERIMENTAL
Intervention: Bofu-tsusho-san (BOF)
Number of subjects: 107
Study 25818388 — intervention group
Group type: COMPARATOR
Intervention: Conventional control therapy
Number of subjects: 107
Study 22684431 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/kg abatacept plus MTX
Number of subjects: 195
Study 22684431 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg/kg abatacept plus MTX
Number of subjects: 195
Study 22684431 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus MTX
Number of subjects: 195
Study 21868617 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP)
Number of subjects: 5061
Study 21868617 — intervention group
Group type: EXPERIMENTAL
Intervention: Albumin
Number of subjects: 5061
Study 21868617 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferritin
Number of subjects: 5061
Study 21868617 — intervention group
Group type: EXPERIMENTAL
Intervention: White blood cell (WBC) count
Number of subjects: 5061
Study 19933725 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding
Number of subjects: 19
Study 19933725 — intervention group
Group type: COMPARATOR
Intervention: Bottle-feeding
Number of subjects: 19
Study 16800349 — intervention group
Group type: EXPERIMENTAL
Intervention: ICL670 (deferasirox) at a dose of 20 to 40 mg/kg
Number of subjects: 0
Study 16800349 — intervention group
Group type: EXPERIMENTAL
Intervention: ICL670 (deferasirox)
Number of subjects: 0
Study 15138373 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopathic treatment (manual techniques including parietal, visceral, and craniosacral techniques)
Number of subjects: 53
Study 15138373 — intervention group
Group type: COMPARATOR
Intervention: Orthopedic treatment (chiropractic techniques, antiphlogistics, and cortison injections)
Number of subjects: 53
Study 11755325 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 30
Study 11755325 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 30
Study 9655732 — intervention group
Group type: EXPERIMENTAL
Intervention: salmeterol 50 microg twice daily (BDP400+salm)
Number of subjects: 177
Study 9655732 — intervention group
Group type: EXPERIMENTAL
Intervention: beclomethasone 200 microg twice daily (BDP800)
Number of subjects: 177
Study 9655732 — intervention group
Group type: COMPARATOR
Intervention: placebo (BDP400) in addition to beclomethasone 200 microg twice daily
Number of subjects: 177
Study 8043993 — intervention group
Group type: COMPARATOR
Intervention: Enflurane anesthesia
Number of subjects: 110
Study 8043993 — intervention group
Group type: EXPERIMENTAL
Intervention: Enflurane anesthesia supplemented by TAES with HANS at Hegu, Yuyao and Fengchi points
Number of subjects: 110
Study 8043993 — intervention group
Group type: EXPERIMENTAL
Intervention: Enflurane anesthesia supplemented by TAES and scalp infiltration with 0.5% procaine
Number of subjects: 110
Study 2899988 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium 0.3 mg/kg
Number of subjects: 205
Study 2899988 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium 0.4 mg/kg
Number of subjects: 205
Study 2899988 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium 0.5 mg/kg
Number of subjects: 205
Study 2899988 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium 0.08 mg/kg
Number of subjects: 205
Study 2899988 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium 0.1 mg/kg
Number of subjects: 205
Study 2899988 — intervention group
Group type: EXPERIMENTAL
Intervention: Succinylcholine 1.0 mg/kg
Number of subjects: 205
Study 29266792 — intervention group
Group type: EXPERIMENTAL
Intervention: Innovative self-management intervention for 4 weeks
Number of subjects: 112
Study 29266792 — intervention group
Group type: COMPARATOR
Intervention: Routine hospital care (Control)
Number of subjects: 112
Study 27312053 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy with cisplatin (25 mg/m² on days 1 and 8), etoposide (60 mg/m² on days 1-3), and irinotecan (90 mg/m² on day 8) for five 2-week courses.
Number of subjects: 180
Study 27312053 — intervention group
Group type: COMPARATOR
Intervention: Topotecan (1.0 mg/m² on days 1-5, every 3 weeks) for four courses.
Number of subjects: 180
Study 27312053 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy group
Number of subjects: 180
Study 27312053 — intervention group
Group type: COMPARATOR
Intervention: Topotecan group
Number of subjects: 180
Study 25284739 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiropractic spinal manipulation
Number of subjects: 24
Study 25284739 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal mobilization
Number of subjects: 24
Study 25284739 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic touch
Number of subjects: 24
Study 25284739 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 24
Study 20636485 — intervention group
Group type: EXPERIMENTAL
Intervention: l‐NMMA (NO synthase inhibitor)
Number of subjects: 9
Study 20636485 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine (α‐receptor agonist)
Number of subjects: 9
Study 20636485 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 20178604 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright light therapy (approximately 10,000 lux for two half-hour sessions daily)
Number of subjects: 0
Study 20178604 — intervention group
Group type: COMPARATOR
Intervention: Placebo (approximately 300 lux for two half-hour sessions daily)
Number of subjects: 0
Study 18502107 — intervention group
Group type: EXPERIMENTAL
Intervention: Lignan complex (500 mg/d of secoisolariciresinol diglucoside)
Number of subjects: 22
Study 18502107 — intervention group
Group type: COMPARATOR
Intervention: Placebo (low-fat muffin without lignan complex)
Number of subjects: 22
Study 15918387 — intervention group
Group type: EXPERIMENTAL
Intervention: Propacetamol 2 g
Number of subjects: 97
Study 15918387 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen 100 mg
Number of subjects: 97
Study 15918387 — intervention group
Group type: EXPERIMENTAL
Intervention: Propacetamol 2 g + Ketoprofen 100 mg
Number of subjects: 97
Study 12686673 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg atorvastatin
Number of subjects: 23
Study 12686673 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg atorvastatin
Number of subjects: 23
Study 12686673 — intervention group
Group type: COMPARATOR
Intervention: Haemodialysis
Number of subjects: 23
Study 10085472 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg melatonin
Number of subjects: 14
Study 10085472 — intervention group
Group type: EXPERIMENTAL
Intervention: melatonin (various doses)
Number of subjects: 14
Study 2488185 — intervention group
Group type: COMPARATOR
Intervention: i.p. urokinase (5000 i.u.)
Number of subjects: 37
Study 2488185 — intervention group
Group type: EXPERIMENTAL
Intervention: CAPD catheter replacement
Number of subjects: 37
Study 884446 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone 200 microgram
Number of subjects: 30
Study 30993660 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone
Number of subjects: 99
Study 30993660 — intervention group
Group type: COMPARATOR
Intervention: Sufentanil
Number of subjects: 99
Study 31077798 — intervention group
Group type: EXPERIMENTAL
Intervention: AOMI (Action Observation and Motor Imagery) for 10 minutes
Number of subjects: 12
Study 31077798 — intervention group
Group type: EXPERIMENTAL
Intervention: AOMI+PAIN (AOMI during hypertonic saline injection)
Number of subjects: 12
Study 31077798 — intervention group
Group type: COMPARATOR
Intervention: PAIN (rest for 10 minutes after hypertonic saline injection)
Number of subjects: 12
Study 27471815 — intervention group
Group type: EXPERIMENTAL
Intervention: Tabalumab 120 mg every 2 weeks (120 Q2W)
Number of subjects: 45
Study 27471815 — intervention group
Group type: EXPERIMENTAL
Intervention: Tabalumab 120 mg every 4 weeks (120 Q4W)
Number of subjects: 45
Study 27471815 — intervention group
Group type: COMPARATOR
Intervention: Placebo every 2 weeks (placebo Q2W)
Number of subjects: 45
Study 25816720 — intervention group
Group type: EXPERIMENTAL
Intervention: Axitinib
Number of subjects: 714
Study 25816720 — intervention group
Group type: COMPARATOR
Intervention: Sorafenib
Number of subjects: 714
Study 24186620 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepilex Lite dressings
Number of subjects: 88
Study 24186620 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 88
Study 20619600 — intervention group
Group type: EXPERIMENTAL
Intervention: T-tube (TT)
Number of subjects: 40
Study 20619600 — intervention group
Group type: COMPARATOR
Intervention: Pressure support (PS)
Number of subjects: 40
Study 20619600 — intervention group
Group type: COMPARATOR
Intervention: Harris-Benedict (HB) equation without activity factor
Number of subjects: 40
Study 20619600 — intervention group
Group type: COMPARATOR
Intervention: Harris-Benedict (HB) equation with activity factor
Number of subjects: 40
Study 19733721 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxcinod 750 mg twice daily
Number of subjects: 916
Study 19733721 — intervention group
Group type: COMPARATOR
Intervention: Naproxcinod 750 mg
Number of subjects: 916
Study 19733721 — intervention group
Group type: COMPARATOR
Intervention: Naproxcinod 375 mg
Number of subjects: 916
Study 19733721 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 916
Study 19733721 — intervention group
Group type: COMPARATOR
Intervention: Naproxen 500 mg twice daily
Number of subjects: 916
Study 17531690 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracameral cefuroxime prophylaxis at 1 mg in 0.1 mL normal saline
Number of subjects: 16603
Study 17531690 — intervention group
Group type: EXPERIMENTAL
Intervention: Clear corneal incisions (CCIs)
Number of subjects: 16603
Study 17531690 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone intraocular lens (IOL) optic material
Number of subjects: 16603
Study 17531690 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical complications
Number of subjects: 16603
Study 17531690 — intervention group
Group type: EXPERIMENTAL
Intervention: Male gender
Number of subjects: 16603
Study 15262827 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin (2x10(6) KIU in pump prime, 2x10(6) KIU loading dose, followed by 0.5x10(6) KIU/h
Number of subjects: 30
Study 15262827 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 30
Study 15262827 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 30
Study 12214358 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief counseling
Number of subjects: 186
Study 12214358 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple advice
Number of subjects: 186
Study 12214358 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 186
Study 9850898 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical tetracaine 0.5% plus intracameral lidocaine 1%
Number of subjects: 59
Study 9850898 — intervention group
Group type: COMPARATOR
Intervention: Topical tetracaine 0.5% plus intracameral BSS
Number of subjects: 59
Study 7978091 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (0.75 g/kg)
Number of subjects: 23
Study 7978091 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 7978091 — intervention group
Group type: EXPERIMENTAL
Intervention: oCRH (1 microgram/kg)
Number of subjects: 23
Study 3377945 — intervention group
Group type: EXPERIMENTAL
Intervention: pethidine 1 mg kg‐1 i.v.
Number of subjects: 25
Study 3377945 — intervention group
Group type: EXPERIMENTAL
Intervention: pethidine 1 mg kg‐1 i.m.
Number of subjects: 25
Study 3377945 — intervention group
Group type: EXPERIMENTAL
Intervention: pethidine 1 mg kg‐1 rectally
Number of subjects: 25
Study 380947 — intervention group
Group type: COMPARATOR
Intervention: Partial closure of the perineal wound and cigarette drainage of the pelvic space (Group A)
Number of subjects: 65
Study 380947 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete suture of the perineal wound and suction drainage of the pelvic space (Group B)
Number of subjects: 65
Study 31806235 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure-controlled ventilation
Number of subjects: 62
Study 31806235 — intervention group
Group type: COMPARATOR
Intervention: Volume-controlled ventilation
Number of subjects: 62
Study 28460544 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose aprotinin
Number of subjects: 40
Study 28460544 — intervention group
Group type: EXPERIMENTAL
Intervention: Early low dose aprotinin
Number of subjects: 40
Study 28460544 — intervention group
Group type: EXPERIMENTAL
Intervention: Late low dose aprotinin
Number of subjects: 40
Study 28460544 — intervention group
Group type: COMPARATOR
Intervention: No aprotinin (control)
Number of subjects: 40
Study 25441397 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg daily for 12 weeks
Number of subjects: 30
Study 25441397 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 30
Study 24118053 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold dry air provocation (CDA) in AR patients
Number of subjects: 0
Study 24118053 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold dry air provocation (CDA) in NAR patients
Number of subjects: 0
Study 24118053 — intervention group
Group type: COMPARATOR
Intervention: Cold dry air provocation (CDA) in healthy controls
Number of subjects: 0
Study 22692637 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle (ILS) program
Number of subjects: 3234
Study 22692637 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (MET) 850 mg twice daily
Number of subjects: 3234
Study 22692637 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLB)
Number of subjects: 3234
Study 20110592 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex antioxidant blend (active treatment) for four months
Number of subjects: 113
Study 20110592 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (identical gel and bottle) for four months
Number of subjects: 113
Study 20110592 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex antioxidant blend (active treatment)
Number of subjects: 113
Study 20110592 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 113
Study 17395870 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular coiling (EVT)
Number of subjects: 2108
Study 17395870 — intervention group
Group type: COMPARATOR
Intervention: Neurosurgical clipping
Number of subjects: 2108
Study 16136166 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Number of subjects: 285
Study 16136166 — intervention group
Group type: EXPERIMENTAL
Intervention: Idarubicin
Number of subjects: 285
Study 16136166 — intervention group
Group type: COMPARATOR
Intervention: Allogeneic bone marrow transplantation (alloBMT)
Number of subjects: 285
Study 16136166 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (without donor)
Number of subjects: 285
Study 16136166 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytogenetic features (favorable, intermediate, unfavorable)
Number of subjects: 285
Study 11903940 — intervention group
Group type: EXPERIMENTAL
Intervention: Single Shot (SS) technique with 0.25 ml x kg(‐1) of 0.25% bupivacaine
Number of subjects: 90
Study 11903940 — intervention group
Group type: EXPERIMENTAL
Intervention: Double Shot (DS) technique with one-third of total dose of bupivacaine given as SS and remaining two-thirds deposited above and lateral to mid‐inguinal point
Number of subjects: 90
Study 10206309 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 4400
Study 10206309 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy plus chemotherapy
Number of subjects: 4400
Study 10829909 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexosaminidase A and B deficiency assessment
Number of subjects: 449
Study 2116082 — intervention group
Group type: EXPERIMENTAL
Intervention: CA 300 mg alone
Number of subjects: 60
Study 2116082 — intervention group
Group type: EXPERIMENTAL
Intervention: CA 200 mg + mitomycin C (MMC) 10 mg
Number of subjects: 60
Study 2116082 — intervention group
Group type: EXPERIMENTAL
Intervention: CA 180 mg + adriamycin (ADM) 20 mg
Number of subjects: 60
Study 387225 — intervention group
Group type: EXPERIMENTAL
Intervention: cis‐dichlorodiammineplatinum(II) (cis‐platinum) at doses of 30 mg/m2
Number of subjects: 140
Study 387225 — intervention group
Group type: EXPERIMENTAL
Intervention: cis‐dichlorodiammineplatinum(II) (cis‐platinum) at doses of 100 mg/m2
Number of subjects: 140
Study 387225 — intervention group
Group type: COMPARATOR
Intervention: Combination of chlorambucil and cis‐platinum (regimen B)
Number of subjects: 140
Study 387225 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of chlorambucil, cis‐platinum, and Adriamycin (regimen C)
Number of subjects: 140
Study 387225 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens (B and C)
Number of subjects: 140
Study 387225 — intervention group
Group type: EXPERIMENTAL
Intervention: cis‐platinum
Number of subjects: 140
Study 31222188 — intervention group
Group type: EXPERIMENTAL
Intervention: Unattended office blood pressure (UBP)
Number of subjects: 308
Study 31222188 — intervention group
Group type: COMPARATOR
Intervention: Conventional attended office blood pressure (CBP)
Number of subjects: 308
Study 25213116 — intervention group
Group type: EXPERIMENTAL
Intervention: Preferred treatment
Number of subjects: 0
Study 25213116 — intervention group
Group type: COMPARATOR
Intervention: Non-preferred treatment
Number of subjects: 0
Study 25066012 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical imiquimod
Number of subjects: 400
Study 25066012 — intervention group
Group type: COMPARATOR
Intervention: MAL‐PDT
Number of subjects: 400
Study 23363492 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgrastim 300 micrograms/day for 7 days
Number of subjects: 59
Study 23363492 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 21876296 — intervention group
Group type: EXPERIMENTAL
Intervention: Stretching device (resting hand splint, finger stretcher, and frame) used for 20 minutes per session, 2 sessions/day, 6 days/week for 3 weeks
Number of subjects: 21
Study 21876296 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified intervention)
Number of subjects: 21
Study 19818599 — intervention group
Group type: EXPERIMENTAL
Intervention: STANDARD (n=279)
Number of subjects: 1016
Study 19818599 — intervention group
Group type: COMPARATOR
Intervention: STANDARD (n=373)
Number of subjects: 1016
Study 19818599 — intervention group
Group type: EXPERIMENTAL
Intervention: TAILORED (n=364)
Number of subjects: 1016
Study 17107904 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorambucil 20 mg m‐2 for 3 days and dexamethasone 4 mg bd for 5 days plus oral idarubicin 10 mg m‐2 for 3 days (CID)
Number of subjects: 200
Study 17107904 — intervention group
Group type: COMPARATOR
Intervention: Chlorambucil 20 mg m‐2 for 3 days and dexamethasone 4 mg bd for 5 days (CD)
Number of subjects: 200
Study 17107904 — intervention group
Group type: EXPERIMENTAL
Intervention: CID
Number of subjects: 200
Study 17107904 — intervention group
Group type: COMPARATOR
Intervention: CD
Number of subjects: 200
Study 17107904 — intervention group
Group type: EXPERIMENTAL
Intervention: CID (B‐cell follicular group)
Number of subjects: 200
Study 17107904 — intervention group
Group type: COMPARATOR
Intervention: CD (B‐cell follicular group)
Number of subjects: 200
Study 14735364 — intervention group
Group type: EXPERIMENTAL
Intervention: Elderly group (70-79 years)
Number of subjects: 194
Study 14735364 — intervention group
Group type: COMPARATOR
Intervention: Younger group (20-29 years)
Number of subjects: 194
Study 14735364 — intervention group
Group type: EXPERIMENTAL
Intervention: Women (elderly)
Number of subjects: 194
Study 14735364 — intervention group
Group type: EXPERIMENTAL
Intervention: Men (elderly)
Number of subjects: 194
Study 14735364 — intervention group
Group type: COMPARATOR
Intervention: Women (younger)
Number of subjects: 194
Study 14735364 — intervention group
Group type: COMPARATOR
Intervention: Men (younger)
Number of subjects: 194
Study 14735364 — intervention group
Group type: EXPERIMENTAL
Intervention: Elderly women
Number of subjects: 194
Study 11768840 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefprozil (15 mg/kg per day in 2 divided doses for 10 days)
Number of subjects: 199
Study 11768840 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin (30 mg/kg per day in 3 divided doses for 10 days)
Number of subjects: 199
Study 11768840 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 199
Study 9407447 — intervention group
Group type: EXPERIMENTAL
Intervention: Benazepril
Number of subjects: 0
Study 8500921 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocloprost (400 micrograms)
Number of subjects: 16
Study 3307308 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (3.0 mg i.v. bolus followed by an i.v. infusion of 4.8 mg/h)
Number of subjects: 8
Study 3307308 — intervention group
Group type: COMPARATOR
Intervention: Insulin (2.4 U/h i.v. infusion over 180 min)
Number of subjects: 8
Study 31702602 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy (NRT) and telephone counseling
Number of subjects: 92
Study 31702602 — intervention group
Group type: COMPARATOR
Intervention: Telephone counseling alone
Number of subjects: 92
Study 28004473 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking programme (Walk Well)
Number of subjects: 19
Study 28004473 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring (using pedometer and diary)
Number of subjects: 19
Study 28004473 — intervention group
Group type: EXPERIMENTAL
Intervention: Role of carers
Number of subjects: 19
Study 27801789 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic supplementation
Number of subjects: 66
Study 27801789 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 24473376 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical pathway of health education
Number of subjects: 116
Study 24473376 — intervention group
Group type: COMPARATOR
Intervention: Traditional health education
Number of subjects: 116
Study 23683751 — intervention group
Group type: EXPERIMENTAL
Intervention: MAL-PDT (methylaminolevulinate photodynamic therapy; two sessions with an interval of 1 week)
Number of subjects: 601